GlassScriptPhysician profile
Bashar Alzahabi
NPI 1467448456
$6,275.64
in general payments reported to CMS, 2019-2025
31 companies · $827 in 2025
The $827 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $355 · 2021: $688 · 2022: $1,188 · 2023: $1,088 · 2024: $1,449 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,364.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,725.61 | 2020-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $697.32 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $565.43 | 2019-2024 | Jynarque |
| Amgen INC. | $493.16 | 2019-2025 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.95 | 2023-2024 | Jardiance |
| Akebia Therapeutics INC | $264.76 | 2019-2024 | Vafseo |
| Daiichi Sankyo INC. | $247.80 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $234.72 | 2019-2024 | Velphoro, Korsuva |
| Vifor Pharma, INC. | $231.25 | 2022-2023 | Veltassa |
| Lilly USA, LLC | $221.51 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $194.88 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $149.18 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $129.09 | 2021-2022 | |
| Gilead Sciences, INC. | $121.43 | 2023 | Epclusa |
| Preventric Diagnostics, INC. | $79.13 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $68.62 | 2022 | |
| Ardelyx, INC. | $57.89 | 2024 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $52.70 | 2019-2023 | Ultomiris |
| Scilex Pharmaceuticals INC. | $48.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.72 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.01 | 2025 | Caplyta |
| Novo Nordisk INC | $39.45 | 2025 | Rybelsus, Ozempic |
| Kaleo, INC. | $37.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.65 | 2019 | |
| Itamar Medical INC | $30.98 | 2022 | |
| Neurocrine Biosciences, INC. | $28.21 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $24.00 | 2024 | Crysvita |
| Xeris Pharmaceuticals, INC. | $23.66 | 2023 | Keveyis |
| Janssen Pharmaceuticals, INC | $16.02 | 2019 | |
| Genzyme Corporation | $13.16 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Alzahabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.